nafarelin and Sarcoma

nafarelin has been researched along with Sarcoma* in 1 studies

Other Studies

1 other study(ies) available for nafarelin and Sarcoma

ArticleYear
Incidental finding of endolymphatic stromal myosis during luteinizing hormone releasing hormone agonist therapy for suspected benign uterine myomata. A case report.
    The Journal of reproductive medicine, 1992, Volume: 37, Issue:12

    A 39-year-old woman with an enlarging myomatous uterus underwent a three-month course of luteinizing hormone releasing hormone (LHRH) agonist treatment. Despite a 50% reduction in uterine size, pathologic examination after uncomplicated hysterectomy revealed a low-grade endometrial stromal sarcoma. As the use of LHRH agonists for myoma reduction increases, delay in the diagnosis of sarcomatous disease will become more widespread. With current available diagnostic modalities, differentiation between sarcomatous and myomatous growth within the uterus is difficult. The possibility of delay in the diagnosis of unsuspected sarcoma when using LHRH agonists is an inherent and apparently unavoidable complication in some cases.

    Topics: Adult; Diagnosis, Differential; Diagnostic Errors; Female; Humans; Leiomyoma; Nafarelin; Sarcoma; Uterine Neoplasms

1992